As part of PharmTech’s coverage of CPHI Milan, Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, ...
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains that developing a molecule requires a ...
High-concentration biologics are pushing the limits of what can be formulated, filled, and delivered as a low-volume ...
Sanofi and Cheplapharm have announced plans for a strategic partnership that would transfer 20 mature medicines and three ...
Keshav Bhutada, chief executive officer of Shilpa CDMO, said the company has long been recognized among existing partners for its capabilities with challenging molecules such as high-potency APIs ...
Christy Owings, vice president and general manager of the Americas business unit, Thermo Fisher Scientific, connected with ...
Since July 2026, the European Union (EU) has shifted its focus from legislative reforms to practical applications, prioritizing supply-chain resilience, preventing medicine shortages, streamlining ...
Christy Owings, vice president and general manager of the Americas business unit at Thermo Fisher Scientific, discusses with ...
Patrik Florencio | Authors | Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.
Novartis obtained portfolio-level options for exclusive rights to Hybrozyme-enabled SC formulations, with economics up to ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol ...
Tara Dougal, event director for pharma at Informa Markets and head of CPHI Milan, previews the 2026 show in an interview with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results